Indaptus Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 12, 2022
Announces Submission of Investigational New Drug (IND) Application for Decoy20 On Track to Initiate Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors in Second Half of 2022 NEW YORK (May 12, 2022) – Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announces financial results for read more →
Indaptus Therapeutics to Present at 2nd Annual Chronic HBV Drug Development
April 20, 2022
NEW YORK (April 20, 2022) – Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announced that Michael J. Newman, Ph.D., Founder and Chief Scientific Officer, will present at the 2nd Annual Chronic HBV Drug Development Summit taking place from April 25-27, 2022 in Boston, MA. Presentation Details: Title: Driving read more →
Indaptus Therapeutics to Present at Maxim Group 2022 Virtual Growth Conference
March 23, 2022
NEW YORK (March 23, 2022) – Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announced that Jeffrey Meckler, Chief Executive Officer, will participate in a pre-recorded presentation at the Maxim Group 2022 Virtual Growth Conference made available Monday, March 28, 2022 at 9:00 a.m. ET. An audio webcast read more →
Indaptus Therapeutics Reports Fourth Quarter and Year End 2021 Financial Results and Provides Corporate Update
March 21, 2022
NEW YORK (March 21, 2022) – Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announces financial results for the fourth quarter and year ended December 31, 2021 and provides a corporate update. “We enter 2022 excited about the future for Indaptus as we continue to advance our clinical read more →
Indaptus Therapeutics to Present at 3rd Annual STING & TLR-Targeting Therapies Summit
March 17, 2022
NEW YORK (March 17, 2022) – Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announced that Michael J. Newman, Ph.D., Founder and Chief Scientific Officer, will present and participate in a panel discussion at the 3rd Annual STING & TLRTargeting Therapies Summit taking place virtually from March 22-24, read more →
Indaptus Therapeutics to Present at 34th Annual ROTH Conference
March 7, 2022
NEW YORK (March 7, 2022) – Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announced that Jeffrey Meckler, Chief Executive Officer, will participate in an on demand pre-recorded presentation at the 34th Annual ROTH Conference which is taking place March 14 – 15, 2022. An audio webcast of read more →
Indaptus Therapeutics to Present at H.C. Wainwright BioConnect 2022 Virtual Conference
January 5, 2022
NEW YORK (January 5, 2022) – Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announced that Jeffrey Meckler, Chief Executive Officer, will participate in a pre-recorded presentation at the H.C. Wainwright BioConnect 2022 Virtual Conference made available on Monday, January 10, 2022 at 7:00 a.m. ET. An audio read more →
Indaptus Therapeutics Announces Appointment of Boyan Litchev, M.D. as Chief Medical Officer
January 3, 2022
Seasoned Drug Developer Brings More Than Twenty Years of Medical Leadership and Clinical Oncology Experience On Track to Initiate Phase 1 Study of Decoy20 in 2022 NEW YORK (January 3, 2022) – Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announces the appointment of Dr. Boyan Litchev, M.D., read more →
Indaptus Therapeutics Appoints Mark Gilbert, M.D., to Board of Directors
December 1, 2021
Former Chief Medical Officer of Juno Therapeutics Brings Decades of Oncology Clinical Development Expertise NEW YORK (December 1, 2021) – Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announces the appointment of Mark Gilbert, M.D., to its Board of Directors. Dr. Gilbert served as Chief Medical Officer of read more →
Indaptus Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 15, 2021
NEW YORK (November 15, 2021) – Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announces financial results for the third quarter ended September 30, 2021 and provides a corporate update. “The third quarter was transformative for Indaptus as we successfully closed the merger with Decoy Biosystems, Inc. (“Decoy”) read more →
© 2021. Indaptus Therapeutics. All Rights Reserved. |